Ph 2 Study of Opaganib and Darolutamide Initiated in metastatic CRPC
“Prostate cancer is the second most diagnosed cancer in the world with around 1.5 million new cases per year, causing the death of almost 400,000 men every year, while millions more men are living with prostate cancer resulting in a significant burden of disease,” said Dr Mark Levitt, RedHill’s Chief Scientific Officer. “Men with mCRPC have few treatment options available to them, and those positive for the PCPro marker of ARPI-resistance seem to have a particularly poor prognosis. Darolutamide is establishing itself as a key therapy in the treatment of prostate cancer, a market worth approximately $12 billion in 2023, and, if the addition of opaganib can reduce the resistance to darolutamide therapy, this could represent a significant breakthrough in improving the ability to manage advanced treatment-resistant mCRPC for improved outcomes.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data